Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
United Orthopedic Corporation (4129.TWO)
New Taipei City, TW
United Orthopedic Corporation is a firm dedicated to the research, development, manufacturing, and global distribution of advanced orthopedic implants and specialized surgical instruments. The company's extensive product offerings address a wide spectrum of orthopedic needs. Its comprehensive range of hip and knee solutions includes various artificial hip joints, partial hip replacements, specialized joints for large trochanteric fractures, and Moore hip prostheses. Uniquely, it also designs and supplies custom artificial hip and knee joints specifically tailored for individual tumor patients, alongside standard artificial knee replacement joints, revision systems, and restricted artificial knee joints. For spinal care, United Orthopedic manufactures vertebral fixation devices. Furthermore, its portfolio extends to injury and trauma products, which encompass a variety of orthopedic internal fixation items, bone plates, bone nails, bone pins, and bone screws. The company also functions as an OEM supplier for orthopedic internal fixation solutions and provides specialized lamb salvage systems. Beyond implants, United Orthopedic Corporation delivers orthopedic surgical equipment and the machinery necessary for its manufacturing. It also trades in special metal and plastic materials, actively engaging in the import and export of its products across international markets. With a global footprint, the company conducts business in Taiwan, across Asia, the Americas, Europe, Africa, and Australia. Established in 1993, United Orthopedic Corporation is headquartered in New Taipei City, Taiwan, and operates as a subsidiary of Chi-Yi Investment Co. Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.08% | -6.99% | -10.44% | -16.16% | -26.85% | -18.04% | -3.97% | +50.25% | +190.05% | +34.23% | +586.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+21.5% ★ Q1'26: +15.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+23.5% Q1'26: -54.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+5.5% ★ Q1'26: -1.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+13.1% ★ Q1'26: +7.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+10.0% ★ Q1'26: +6.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+2.0% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.61× Q1'26: 4.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.39B
est.
|
1.42B
est: 1.35B (+4.6%)
|
1.97B
est: 1.97B (-0.4%)
|
2.32B
est: 2.33B (-0.6%)
|
2.45B
est: 2.42B (+1.3%)
|
2.35B
est: 2.34B (+0.4%)
|
2.57B
est: 2.57B (+0.1%)
|
3.16B
est: 3.16B (+0.0%)
|
3.93B
est: 3.93B (0.0%)
|
4.65B
est: 4.69B (-0.8%)
|
5.66B
est: 5.68B (-0.5%)
|
6.77B
6.77B – 6.77B
+19.2% YoY
|
8.05B
8.05B – 8.05B
+18.8% YoY
|
| EBITDA |
286.79M
est.
|
263.23M
est: 279.02M (-5.7%)
|
312.33M
est: 406.83M (-23.2%)
|
299.58M
est: 480.92M (-37.7%)
|
394.23M
est: 499.07M (-21.0%)
|
376.68M
est: 481.85M (-21.8%)
|
471.16M
est: 530.21M (-11.1%)
|
676.84M
est: 651.68M (+3.9%)
|
949.84M
est: 810.62M (+17.2%)
|
1.08B
est: 1.29B (-16.5%)
|
1.28B
est: 1.56B (-18.2%)
|
1.87B
1.87B – 1.87B
+19.2% YoY
|
2.22B
2.22B – 2.22B
+18.8% YoY
|
| EBIT |
134.28M
est.
|
159.69M
est: 130.64M (+22.2%)
|
161.94M
est: 190.48M (-15.0%)
|
84.80M
est: 225.17M (-62.3%)
|
124.12M
est: 233.66M (-46.9%)
|
89.88M
est: 225.60M (-60.2%)
|
161.43M
est: 248.24M (-35.0%)
|
341.58M
est: 305.11M (+12.0%)
|
553.37M
est: 379.53M (+45.8%)
|
618.29M
est: 963.70M (-35.8%)
|
740.72M
est: 1.17B (-36.6%)
|
1.39B
1.39B – 1.39B
+19.2% YoY
|
1.65B
1.65B – 1.65B
+18.8% YoY
|
| Net Income |
200.93M
est.
|
146.60M
est: 177.46M (-17.4%)
|
130.26M
est: 211.03M (-38.3%)
|
127.55M
est: 160.48M (-20.5%)
|
88.58M
est: 130.69M (-32.2%)
|
101.83M
est: 89.85M (+13.3%)
|
52.27M
est: 29.79M (+75.5%)
|
221.53M
est: 226.79M (-2.3%)
|
384.20M
est: 421.48M (-8.8%)
|
456.43M
est: 494.82M (-7.8%)
|
562.50M
est: 591.07M (-4.8%)
|
713.60M
703.88M – 723.32M
+20.7% YoY
|
846.91M
846.91M – 846.91M
+18.7% YoY
|
| SGA |
824.16M
est.
|
597.47M
est: 801.83M (-25.5%)
|
962.65M
est: 1.17B (-17.7%)
|
1.17B
est: 1.38B (-15.3%)
|
1.28B
est: 1.43B (-10.8%)
|
1.40B
est: 1.38B (+0.9%)
|
1.54B
est: 1.52B (+0.9%)
|
1.85B
est: 1.87B (-1.4%)
|
2.31B
est: 2.33B (-0.6%)
|
2.78B
est: 2.78B (-0.2%)
|
3.40B
est: 3.37B (+0.8%)
|
4.02B
4.02B – 4.02B
+19.2% YoY
|
4.78B
4.78B – 4.78B
+18.8% YoY
|
| EPS |
2.09
est.
|
2.01
est: 1.85 (+8.8%)
|
1.78
est: 2.20 (-18.9%)
|
1.61
est: 1.67 (-3.6%)
|
1.05
est: 1.36 (-22.8%)
|
1.00
est: 0.94 (+7.0%)
|
0.37
est: 0.31 (+19.4%)
|
2.84
est: 2.36 (+20.3%)
|
4.56
est: 4.39 (+4.0%)
|
4.75
est: 5.05 (-5.9%)
|
5.83
est: 6.03 (-3.3%)
|
7.28
7.18 – 7.38
+20.7% YoY
|
8.64
8.64 – 8.64
+18.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 17.2K | 0.42% |
| 2 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 19.5K | 0.35% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 23.2K | 0.56% |
| 4 | Avantis Emerging Markets Value ETF AVES | 0.01% | 86.2K | 0.36% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 95.6K | 0.46% |
| 6 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 17.2K | 0.33% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 353.6K | 0.39% |
| 8 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 8.6K | 0.33% |
| 9 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 20.3K | 0.44% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 222.9K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deqiong Lin | Vice President & Director | 12M | male |
| Chien-Chong Liao | Vice President | 8M | male |
| Chih Chieh Cheng | Chief Information Security Officer | — | — |
| Lin Terchien | President & Manager | — | — |
| Yuan-Chang Deng | Divisional Head of Department of Finance & Accounting and Accounting Supervisor | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4129.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
